342 related articles for article (PubMed ID: 38669388)
1. Interplay of human gastrointestinal microbiota metabolites: Short-chain fatty acids and their correlation with Parkinson's disease.
Liu J; Chen Q; Su R
Medicine (Baltimore); 2024 Apr; 103(17):e37960. PubMed ID: 38669388
[TBL] [Abstract][Full Text] [Related]
2. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease.
Aho VTE; Houser MC; Pereira PAB; Chang J; Rudi K; Paulin L; Hertzberg V; Auvinen P; Tansey MG; Scheperjans F
Mol Neurodegener; 2021 Feb; 16(1):6. PubMed ID: 33557896
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
Kalyanaraman B; Cheng G; Hardy M
Redox Biol; 2024 May; 71():103092. PubMed ID: 38377788
[TBL] [Abstract][Full Text] [Related]
4. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations.
van de Wouw M; Boehme M; Lyte JM; Wiley N; Strain C; O'Sullivan O; Clarke G; Stanton C; Dinan TG; Cryan JF
J Physiol; 2018 Oct; 596(20):4923-4944. PubMed ID: 30066368
[TBL] [Abstract][Full Text] [Related]
5. Short-chain fatty acids: Important components of the gut-brain axis against AD.
Huang Y; Wang YF; Miao J; Zheng RF; Li JY
Biomed Pharmacother; 2024 Jun; 175():116601. PubMed ID: 38749177
[TBL] [Abstract][Full Text] [Related]
6. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders.
Yadav S; Dwivedi A; Tripathi A; Tripathi AK
Nutr Res; 2022 Oct; 106():72-84. PubMed ID: 36152586
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Short-chain Fatty Acids and Parkinson's Disease: A Review from Pathology to Clinic.
Duan WX; Wang F; Liu JY; Liu CF
Neurosci Bull; 2024 Apr; 40(4):500-516. PubMed ID: 37755674
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review.
Rauf A; Khalil AA; Rahman UU; Khalid A; Naz S; Shariati MA; Rebezov M; Urtecho EZ; de Albuquerque RDDG; Anwar S; Alamri A; Saini RK; Rengasamy KRR
Crit Rev Food Sci Nutr; 2022; 62(22):6034-6054. PubMed ID: 33703960
[TBL] [Abstract][Full Text] [Related]
10. Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.
Raj K; Singh S; Chib S; Mallan S
Curr Pharm Des; 2022; 28(37):3049-3067. PubMed ID: 36200207
[TBL] [Abstract][Full Text] [Related]
11. Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease.
Cong J; Zhou P; Zhang R
Nutrients; 2022 May; 14(9):. PubMed ID: 35565943
[TBL] [Abstract][Full Text] [Related]
12. Gut microbial metabolites SCFAs and chronic kidney disease.
He M; Wei W; Zhang Y; Xiang Z; Peng D; Kasimumali A; Rong S
J Transl Med; 2024 Feb; 22(1):172. PubMed ID: 38369469
[TBL] [Abstract][Full Text] [Related]
13. Gut brain axis: an insight into microbiota role in Parkinson's disease.
Moustafa SA; Mohamed S; Dawood A; Azar J; Elmorsy E; Rizk NAM; Salama M
Metab Brain Dis; 2021 Oct; 36(7):1545-1557. PubMed ID: 34370175
[TBL] [Abstract][Full Text] [Related]
14. Short-chain fatty acids affect the development of inflammatory bowel disease through intestinal barrier, immunology, and microbiota: A promising therapy?
Peng K; Xia S; Xiao S; Yu Q
J Gastroenterol Hepatol; 2022 Sep; 37(9):1710-1718. PubMed ID: 35906780
[TBL] [Abstract][Full Text] [Related]
15. Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration.
Mahbub NU; Islam MM; Hong ST; Chung HJ
Front Cell Infect Microbiol; 2024; 14():1348279. PubMed ID: 38435303
[TBL] [Abstract][Full Text] [Related]
16. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health.
Nogal A; Valdes AM; Menni C
Gut Microbes; 2021; 13(1):1-24. PubMed ID: 33764858
[TBL] [Abstract][Full Text] [Related]
17. Short chain fatty acids: Microbial metabolites for gut-brain axis signalling.
O'Riordan KJ; Collins MK; Moloney GM; Knox EG; Aburto MR; Fülling C; Morley SJ; Clarke G; Schellekens H; Cryan JF
Mol Cell Endocrinol; 2022 Apr; 546():111572. PubMed ID: 35066114
[TBL] [Abstract][Full Text] [Related]
18. Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism.
Su SH; Wu YF; Lin Q; Zhang L; Wang DP; Hai J
J Neuroinflammation; 2022 Dec; 19(1):313. PubMed ID: 36567333
[TBL] [Abstract][Full Text] [Related]
19. The gut-lung axis in severe acute Pancreatitis-associated lung injury: The protection by the gut microbiota through short-chain fatty acids.
Wang Z; Liu J; Li F; Luo Y; Ge P; Zhang Y; Wen H; Yang Q; Ma S; Chen H
Pharmacol Res; 2022 Aug; 182():106321. PubMed ID: 35752356
[TBL] [Abstract][Full Text] [Related]
20. The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids.
Xiao W; Su J; Gao X; Yang H; Weng R; Ni W; Gu Y
Microbiome; 2022 Apr; 10(1):62. PubMed ID: 35430804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
